As of June, 4 Analysts See $-0.65 EPS for Sonoma Pharmaceuticals, Inc. (SNOA)

May 17, 2018 - By Steve Marquez

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) is anticipated to report earnings on June, 4., according to Zacks. Analysts expect change of 5.80 % or $0.04 from previous year’s $-0.69 EPS compared to current’s $-0.65 EPS. Wall Street now forecasts -10.96 % EPS growth despite Sonoma Pharmaceuticals, Inc. last quarter’s EPS of $-0.73. The stock decreased 1.05% or $0.04 during the last trading session, hitting $3.78.Currently Sonoma Pharmaceuticals, Inc. is downtrending after 45.71% change in last May 17, 2017. SNOA has also 11,989 shares volume. The stock underperformed the S&P500 by 57.26%.

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally.The firm is worth $17.93 million. The firm offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains.Last it reported negative earnings. The Company’s products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis.

More recent Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) news were announced by Globenewswire.com, Globenewswire.com and Streetinsider.com. The first one has “Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer” as a title and was announced on May 08, 2018. The next is “Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products” on April 17, 2018. And last was announced on May 08, 2018, called “Sonoma Pharmaceuticals (SNOA) Appoints Marc Umscheid COO”.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: